Navigation Links
Newly discovered antibody may be body's natural defense against Alzheimer's

In an important advance in the battle against Alzheimer's disease, physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center have identified naturally occurring antibodies in human blood that may help to defend against this form of dementia as well as other neurodegenerative diseases.

The newly found antibodies selectively target aggregates of beta amyloid proteins called "oligomers" that are toxic to brain cells, while ignoring the benign single-molecule forms of the same proteins. The existence of such antibodies was predicted by animal studies, but they were never previously demonstrated to be present in substantial quantities in blood from normal humans.

Lead researcher Dr. Norman Relkin, a behavioral neurologist and neuroscientist at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, will present the findings on Monday, June 11, at 3:30 pm, at the "2nd Alzheimer's Association International Conference on Prevention of Dementia," in Washington, DC.

Dr. Relkin is director of the Memory Disorders Program at NewYork-Presbyterian/Weill Cornell and associate professor of clinical neurology at Weill Cornell Medical College.

Dr. Relkin's team has been testing an antibody-based immunotherapy called Intravenous Immunoglobulin (IVIG) as a potential new treatment for Alzheimer's. IVIG is made from the blood of healthy donors and was previously reported to contain small quantities of antibodies against beta amyloid.

"The effects of IVIG in lowering beta amyloid levels in Alzheimer's patients in our Phase I clinical trial were much more profound than we expected," Dr. Relkin explains. "We couldn't readily explain this based on the low levels of anti-amyloid antibodies known to be present in IVIG. We suspected there might be another, unseen player."

His laboratory studies demonstrated that IVIG initially bound very little single-molecule ("monomer") beta amyloid in a test tube.
'"/>

Source:New York- Presbyterian Hospital/Columbia University Medical Center


Page: 1 2 3

Related biology news :

1. Newly-discovered class of genes determines ?and restricts ?stem cell fate
2. Newly discovered virus linked to childhood lung disorders and Kawasaki disease
3. Newly Discovered Compound Blocks Known Cancer-Causing Protein
4. Newly discovered pathway might help in design of cancer drugs
5. Newly Discovered Branding Process Helps Immune System Cells Pick Their Fights
6. Newly discovered protein an important tool for sleeping sickness research
7. Newly discovered genetic disease sheds light on bodys water balance
8. Newly Discovered Role for Heart Response Enzyme May Yield Better Heart Failure Therapy
9. Newly recognized gene mutation may reduce seeds, resurrect plants
10. Newly discovered birdlike dinosaur is oldest raptor ever found in South America
11. Fitting in: Newly evolved genes adopt a variety of strategies to remain in the gene pool

Post Your Comments:
(Date:11/20/2009)... Research Center (ERC) has been awarded a grant fr...methods of recovering and reusing the heat that wo...pression process in a carbon capture system. The g...n capture and sequestration, or storage (CCS), and... emitted into the atmosphere by coal-fired power p...
(Date:11/19/2009)...ists are revealing the genetic instructions inside... maize, has one of the most complex sequences of D...ison genomicist David Schwartz, who was one of mor...Science . , "The maize genome is a true maze fu...oubled would-be sequencers for years," says Schwar...
(Date:11/19/2009)...ov. 19 BIO-key Internati... wireless public safety and finger-based biometric...ial Shareholder Meeting held today was adjourned w... not present. ,, (Logo: http://www.newscom.com...impressive 99.3% of the 35 million votes cast vote...
Breaking Biology News(10 mins):Lehigh receives grant to reduce cost of carbon capture at coal-fired power plants 2Lehigh receives grant to reduce cost of carbon capture at coal-fired power plants 3Sweet corn story begins in UW-Madison lab 2Sweet corn story begins in UW-Madison lab 3BIO-key(R) Provides Update to Special Shareholder Meeting 2BIO-key(R) Provides Update to Special Shareholder Meeting 3Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 1Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 2Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 3Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 4Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 5Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 6Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 7Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 8Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 9Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 10Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 11Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 12Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 13Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 14Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 15Judge Halts IHSS Home Care Cuts 3B Says They Likely Violate Federal Law 59781 1Judge Halts IHSS Home Care Cuts 3B Says They Likely Violate Federal Law 59781 2Checkered history of mother and daughter cells explains cell cycle differences 10424 1Checkered history of mother and daughter cells explains cell cycle differences 10424 2Checkered history of mother and daughter cells explains cell cycle differences 10424 3
... marine creatures in the vast, dark deep-sea surro...ming worms, crustaceans, and molluscs living in th...ion of ocean life. , Reporting this week in the jo... the deeper parts of the Southern Ocean - the sour...are likely to be related to animals living in both...
... potentially valuable organisms are at risk from s...de, says a new study led by a University of Toront...hide deposits near "black smokers"—undersea hydrot...ater into the frigid deep-sea environment, and sup...clam species—could smother and contaminate these c...
...and control yellow fever and dengue fever has beco...draft of the genome sequence of Aedes aegypti mosq...nstitute for Genomic Research (TIGR) and David Sev...is the complete set of genetic material including ... The research appears in the May 18, 2007 Science ...
Other Biology News:Scientists discover new life in the Antarctic deep sea 2Study warns deep-sea mining may pose serious threat to fragile marine ecosystems 2Study warns deep-sea mining may pose serious threat to fragile marine ecosystems 3Genome of yellow fever/dengue fever mosquito sequenced 2Genome of yellow fever/dengue fever mosquito sequenced 3
(Date:11/18/2009)...RNewswire/ -- Reportlinker.com announces that a ne...ogue. ,, Biotechnology Reagents - A Global Ma....com/p0164375/Biotechnology-Reagents---A-Global-Ma...m_medium=pr&utm_campaign=prnewswire ,, Re...compounds used in a range of biotech related areas...
(Date:11/18/2009)...rporation and SwitchGear Genomics announce a novel...s. , Madison, WI, USA (PR...SwitchGear Genomics announce a novel method for ch...a study using the HaloCHIP™ System and high-... to correlate DNA binding events to transcriptiona...
(Date:11/18/2009)...uces key cardiac enzymes at multiple time points a...eart Association 2009 Scientific Sessions , L...cs Inc., a biotechnology company pioneering the de...s derived from pathogens, today reported results f...Serp-1), an anti-inflammatory protein derived from...
(Date:11/18/2009)...Newswire-FirstCall/ -- Champions Biotechnology, I...development company with a predictive preclinical ... enhancing the value of oncology drugs, has establ...niversity and Southern Research Institute for the ...ientists from Yale and Southern Research found tha...
Breaking Biology Technology:Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 2Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 3Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 4Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 5Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 6Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 7Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 8Promega and SwitchGear Publish Findings from Combined Technologies that Correlate Binding Events and Transcriptional Activity 2Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 2Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 3Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 4Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology 2Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology 3Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology 4
...g and diagnostic discovery company, has completed ...isease test. The company expects to have,this test...LP (Good,Laboratory Practices) compliant laborator...9. This initial ExonHit test aims to identify pat...mple blood sample. Further developments are,underw...
...vations, Inc. (Amex: IMA ), announced today that ... conditions, 7,000,000 shares of its common,stock ...ent in an,underwritten public offering. Certain se...g to sell up to 165,698 shares of common stock in ...erwriters a 30-day option to,purchase up to an add...
...Advocating Use of Hand Cleansers With CHG f...a., Nov. 8 Headlines call MRSA (methicillin-,resi...nd the media continue,to report daily on recent sc...nt deaths due to this drug-resistant staph infecti...of the best means of preventing a,MRSA-related ski...
Other Biology Technology:ExonHit Completes a Prototype to Detect Alzheimer's Disease From Blood 2ExonHit Completes a Prototype to Detect Alzheimer's Disease From Blood 3ExonHit Completes a Prototype to Detect Alzheimer's Disease From Blood 4Inverness Medical Innovations Announces Proposed Public Offering of Common Stock 2Inverness Medical Innovations Announces Proposed Public Offering of Common Stock 3Soap and Water May not be Enough to Fight MRSA Superbug 2Soap and Water May not be Enough to Fight MRSA Superbug 3
Sheep Anti-Staphylococcus DNase Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-zona radiata Monoclonal Antibody, Unconjugated, Clone MN-8C4 from Abcam
Rabbit Anti-KIAA1276 Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-Chk1, phospho (Ser296) Polyclonal Antibody, Unconjugated from Cell Signaling Technology
Biology Products: